Insider Selling: ASP Isotopes (NASDAQ:ASPI) Director Sells $188,100.00 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) Director Michael Gorley sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the transaction, the director owned 87,908 shares of the company’s stock, valued at approximately $551,183.16. This represents a 25.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ASP Isotopes Price Performance

ASPI stock opened at $5.63 on Friday. The stock has a 50-day simple moving average of $6.26 and a two-hundred day simple moving average of $5.90. ASP Isotopes Inc. has a twelve month low of $3.92 and a twelve month high of $14.49. The firm has a market capitalization of $708.82 million, a PE ratio of -2.71 and a beta of 3.51. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The firm had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million.

Institutional Investors Weigh In On ASP Isotopes

Several hedge funds have recently bought and sold shares of ASPI. Pacer Advisors Inc. grew its stake in ASP Isotopes by 24.6% in the 1st quarter. Pacer Advisors Inc. now owns 503,925 shares of the company’s stock worth $2,227,000 after buying an additional 99,553 shares in the last quarter. Empowered Funds LLC raised its position in shares of ASP Isotopes by 38.2% during the 1st quarter. Empowered Funds LLC now owns 185,953 shares of the company’s stock valued at $822,000 after buying an additional 51,351 shares in the last quarter. Royal Bank of Canada raised its position in shares of ASP Isotopes by 18.4% during the 1st quarter. Royal Bank of Canada now owns 37,954 shares of the company’s stock valued at $167,000 after buying an additional 5,906 shares in the last quarter. Encompass Capital Advisors LLC purchased a new stake in shares of ASP Isotopes during the 1st quarter valued at $30,551,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of ASP Isotopes by 8.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 30,503 shares of the company’s stock worth $135,000 after acquiring an additional 2,470 shares during the last quarter. 16.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on ASPI. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.